Alembic Pharmaceuticals announces USFDA Tentative Approval for Bosutinib Tablets
Mumbai, 1st July 2024: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bosutinib Tablets, 100 mg and 500 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Bosulif Tablets, 100 mg […]
Alembic Pharmaceuticals announces USFDA Tentative Approval for Bosutinib Tablets Read More »
